青斑样血管病的传统治疗主要有系统性使用抗凝药物、抗血小板药物、免疫抑制剂、糖皮质激素及物理治疗等,常因不良反应及疗效不佳而使用受限。近年来,小分子靶向药物(JAK抑制剂)已经被越来越多用于治疗炎症性皮肤病,取得满意的临床效果...青斑样血管病的传统治疗主要有系统性使用抗凝药物、抗血小板药物、免疫抑制剂、糖皮质激素及物理治疗等,常因不良反应及疗效不佳而使用受限。近年来,小分子靶向药物(JAK抑制剂)已经被越来越多用于治疗炎症性皮肤病,取得满意的临床效果及良好的安全性。本文报道JAK1抑制剂阿布希替尼治疗青斑样血管病1例,并回顾相关文献。The traditional treatment of livedoid vasculopathy mainly includes systemic use of anticoagulants, antiplatelet drugs, immunosuppressive agents, glucocorticoids and physical therapy, which is often limited due to adverse reactions and poor efficacy. In recent years, small molecule targeted drugs (JAK inhibitors) have been more and more used in the treatment of inflammatory skin diseases, achieving satisfactory clinical results and good safety. This paper reports the treatment of JAK 1 inhibitor Abxitinib in a case of blue spot-like vascular disease, and reviews the relevant literature.展开更多
文摘青斑样血管病的传统治疗主要有系统性使用抗凝药物、抗血小板药物、免疫抑制剂、糖皮质激素及物理治疗等,常因不良反应及疗效不佳而使用受限。近年来,小分子靶向药物(JAK抑制剂)已经被越来越多用于治疗炎症性皮肤病,取得满意的临床效果及良好的安全性。本文报道JAK1抑制剂阿布希替尼治疗青斑样血管病1例,并回顾相关文献。The traditional treatment of livedoid vasculopathy mainly includes systemic use of anticoagulants, antiplatelet drugs, immunosuppressive agents, glucocorticoids and physical therapy, which is often limited due to adverse reactions and poor efficacy. In recent years, small molecule targeted drugs (JAK inhibitors) have been more and more used in the treatment of inflammatory skin diseases, achieving satisfactory clinical results and good safety. This paper reports the treatment of JAK 1 inhibitor Abxitinib in a case of blue spot-like vascular disease, and reviews the relevant literature.
